Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the efficacy of YM155 based on objective tumor response rate (CR+PR) in patients with measurable disease based on RECIST criteria
Critère d'inclusion
- Confirmed locally advanced or metastatic Non-Small Cell Lung Cancer, which is stage IIIB or stage IV disease not curable with surgery or radiotherapy at study entry